Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant Melanoma

Abstract excerpt

<h4>ABSTRACT</h4> BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti–PD-1/anti-CTLA-4) have transformed the treatment of BRAF -mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. In this study, we analyzed pre-treatment tumor samp...

Topics

Open a Topic to create a Post that cites this publication.

• Carcinogenesis
• Drug Resistance, Neoplasm
• I-kappa B Kinase
• MAP Kinase Signaling System
• Melanoma
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf
• Xenograft Model Antitumor Assays

Identifiers and source

Literature Corpus work

88f3bc90-361e-5cae-b2ec-568f2427cb54

DOI

10.64898/2026.05.09.721157